Pharmacyte Biotech Inc (OTCMKTS:PMCB) has a valid reason to cheer as a major research paper that appeared in ‘Molecular Therapy – Methods & Clinical Development’ has highlighted the company’s technology in reversing the diabetes. The extensive research undertaken by Prof. Ann Simpson with the University of Technology Sydney (UTS) and the University of Sydney in Australia shows the efficacy of “Melligen” cells in treating Type 1 diabetes.

Reversal of Diabetes

The research paper was released under the title “Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen Cells.” The research team drew conclusions that Melligen cell line, which exists in human liver cells, has the capability of producing insulin and regulation blood glucose (sugar) levels. The authors of the paper claimed that such cell line can reverse the diabetes.

During the research process, the team used Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s technology, which is based on live-cell encapsulation method known as ‘Cell-in-a-Box (R)’. The team conducted various tests throughout the multiple stages of the development process to confirm that Melligen cells released insulin in response to concentrations of glucose. The study included transplantation of Melligen cells into diabetic mice that had non-functioning immune systems. Results showed that following the transplantation, the blood glucose levels of the mice was restored to normal levels.

Study positive for the company

The most important point noted by the study was that Melligen cells are required to be protected from the rejection of the immune system after being introduced in the body. The authors suggested that this could be achieved through encapsulating the cells in “cocoons” before introducing them into a diabetic patient’s system. The indication seemed to be positive for Pharmacyte Biotech Inc (OTCMKTS:PMCB), which provides cell encapsulation technology.

Following the release of the research paper, Pharmacyte Biotech Inc (OTCMKTS:PMCB) stock jumped by 8.27% to $0.156 with an average traded share volume of 2.73 million.